Ochnaflavone
Based on 1 Customer Validation
Ochnaflavone is an inhibitor of IIA-type secretory phospholipase A2 (sPLA2-IIA) with an IC50 of 3.45 µM. Ochnaflavone exhibits significant anti-inflammatory and liver-protective effects, capable of inhibiting the degradation of phosphatidylethanolamine (PE) and lipid peroxidation induced by carbon tetrachloride (CCl4) in rat liver, with an IC50 of 7.16 µM for lipid peroxidation. Ochnaflavone can be used in research on liver damage and inflammatory diseases.
For research use only. We do not sell to patients.
- Purity : 98.30%
- CAS No.: 50276-96-5
- Formula: C30H18O10
- Molecular Weight:538.46
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Phospholipase Isoforms
More
Biological Activity
Description
IC50 & Target
|
sPLA2 3.45 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
>100 μM
Compound: ochanflavone
|
Inhibition of human cloned cPLA2 expressed in HEK293 cells
Inhibition of human cloned cPLA2 expressed in HEK293 cells
|
[PMID: 17826099] |
| HEK293 | IC50 |
>100 μM
Compound: ochanflavone
|
Inhibition of human cloned sPLA2-10 expressed in HEK293 cells
Inhibition of human cloned sPLA2-10 expressed in HEK293 cells
|
[PMID: 17826099] |
| HEK293 | IC50 |
>100 μM
Compound: ochanflavone
|
Inhibition of rat cloned sPLA2-1B expressed in HEK293 cells
Inhibition of rat cloned sPLA2-1B expressed in HEK293 cells
|
[PMID: 17826099] |
| HEK293 | IC50 |
17.6 μM
Compound: ochanflavone
|
Inhibition of human cloned sPLA2-5 expressed in HEK293 cells
Inhibition of human cloned sPLA2-5 expressed in HEK293 cells
|
[PMID: 17826099] |
| HEK293 | IC50 |
3.5 μM
Compound: Ochnaflavone
|
Inhibition of sPLA2-2A in HEK293 cell
Inhibition of sPLA2-2A in HEK293 cell
|
[PMID: 16504502] |
| MCF7 | IC50 |
54.5 μM
Compound: 3
|
Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay
|
[PMID: 34875389] |
Chemical Information
-
CAS No. 50276-96-5
-
Appearance Solid
-
Molecular Weight 538.46
-
Formula C30H18O10
-
Color Yellow to brown
-
SMILES
O=C1C=C(C2=CC=C(OC3=CC(C4=CC(C5=C(O)C=C(O)C=C5O4)=O)=CC=C3O)C=C2)OC6=CC(O)=CC(O)=C16
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (185.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Hepatotoxicity Study
This protocol evaluates hepatotoxicity using complementary in vivo mouse APAP acute liver injury and in vitro hepatocyte-based cytotoxicity readouts. In vivo APAP injury is assessed by serum ALT/AST, liver histology, hepatic glutathione, protein adducts, necrosis, inflammation, and regeneration-related endpoints. In vitro hepatotoxicity is assessed by loss of viability, leakage of ALT/AST/LDH, oxidative-stress markers, mitochondrial function, nuclear morphology, intracellular calcium, and high-content imaging endpoints.
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8571 mL | 9.2857 mL | 18.5715 mL | 46.4287 mL |
| 5 mM | 0.3714 mL | 1.8571 mL | 3.7143 mL | 9.2857 mL | |
| 10 mM | 0.1857 mL | 0.9286 mL | 1.8571 mL | 4.6429 mL | |
| 15 mM | 0.1238 mL | 0.6190 mL | 1.2381 mL | 3.0952 mL | |
| 20 mM | 0.0929 mL | 0.4643 mL | 0.9286 mL | 2.3214 mL | |
| 25 mM | 0.0743 mL | 0.3714 mL | 0.7429 mL | 1.8571 mL | |
| 30 mM | 0.0619 mL | 0.3095 mL | 0.6190 mL | 1.5476 mL | |
| 40 mM | 0.0464 mL | 0.2321 mL | 0.4643 mL | 1.1607 mL | |
| 50 mM | 0.0371 mL | 0.1857 mL | 0.3714 mL | 0.9286 mL | |
| 60 mM | 0.0310 mL | 0.1548 mL | 0.3095 mL | 0.7738 mL | |
| 80 mM | 0.0232 mL | 0.1161 mL | 0.2321 mL | 0.5804 mL | |
| 100 mM | 0.0186 mL | 0.0929 mL | 0.1857 mL | 0.4643 mL |
Ochnaflavone Related Classifications
HY-N7327 Related Classifications
Powered by Bioz